EGFR and non-small cell lung carcinoma: Previous reports showed that anti-CTLA4 antibodies may induce PD-L1 expression in NSCLC with wild-type EGFR and high expression of CTLA4, which enhances the efficacy of anti-PD-1 therapy [82].